AIM
SVA

Acrospire Investment Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Acrospire Investment Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,030
Closed -$34K – 2141
2017
Q2 		$34K Sell
5,030
-4,054
-45% -$22.2K 0.03% 1208
2017
Q1 		$52K Sell
9,084
-10,035
-52% -$58.1K 0.04% 922
2016
Q4 		$113K Buy
+19,119
New +$115K 0.05% 839

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acrospire Investment Management's SVA Position: Q3 2017 in Review

Acrospire Investment Management sold out of Sinovac Biotech, Ltd (SVA) in Q3 2017, closing a stake of 5,030 shares — an estimated $34K sold.

Acrospire Investment Management first reported a position in SVA in Q4 2016 and held it in 3 quarters. The position peaked at $113K in Q4 2016. 35 funds tracked by Wall St. Rank hold SVA as of Q3 2017.

  • Acrospire Investment Management reported no remaining Sinovac Biotech, Ltd position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 5,030 Sinovac Biotech, Ltd shares in Q3 2017, an estimated $34K.
  • Acrospire Investment Management first reported a position in Sinovac Biotech, Ltd in Q4 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Sinovac Biotech, Ltd position peaked at $113K in Q4 2016.
  • 35 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.